20-quarter listed-company comparison

Pharma - API Stocks in India

Pharma - API: Aarti Drugs Ltd owns the largest revenue base; Ind-Swift Laboratories Ltd has the fastest current growth.

01 · the index people search for

Nifty Pharma - API Index — Constituents & Performance

The Pharma - API companies below are the listed Indian Pharma - API universe this page tracks — the same constituent set people search for as the Nifty Pharma - API index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.

02 · the sector itself · before any single company

How has Pharma - API moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 45% ahead of NIFTY 500. Earnings across its companies fell 9% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 19 weeks running.

LEADER · ahead 19w~Price up, without the fundamentals confirming10 of 14 companies ahead of NIFTY 500 by 5% or more over three months

RS ↑19w · 12/14 >200d (−1) · 10/14 lead (−2) · EPS 6/14↑

Pharma - API, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 14 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Pharma - API outperforming NIFTY 500?

Pharma - API has outperformed NIFTY 500 by 27.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 26%. 11 of 14 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Ind-Swift Laboratories Ltd is the strongest against the sector itself at +74.8%. Readings are as of 2026-08-09.

+26.0%Sector vs NIFTY 500 · 13 weeks

+27.3%Sector vs NIFTY 500 · 52 weeks

11/14Stocks leading NIFTY 500

5/14Stocks leading sector

Sector metric: 40.7 as of 2026-08-09 · CONSOLIDATION · falling.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Pharma - API has outperformed NIFTY 500 by 27.3% over 52 weeks and 26% over 13 weeks. 11 of 14 covered companies beat NIFTY on Mansfield relative strength, while 5 of 14 beat the sector itself. Aarti Drugs Ltd leads with revenue of ₹2,678 crore, based on 14 of 14 comparable companies through Jun 2026.

Companies

complete canonical membership

Combined market value

₹49.9K Cr

Orchid Pharma Ltd

Revenue growing

11/14

positive TTM year-on-year growth

Beating NIFTY 500

11/14

positive Mansfield relative strength

Comparing 5 of 14

04 · research priority, made explicit

Best Pharma - API Stocks in India (Aug 2026), Ranked by Data

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

Senores Pharmaceuticals Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 75.3% evidence confidence.

Fermenta Biotech Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

Top 10 Pharma - API Stocks in India

Company	Score	Price stage	Growth & earnings/35	Capital efficiency/25	Valuation/20	Relative strength/20
1Senores Pharmaceuticals LtdSENORES	73.2/100Favorable setup75% evidence	LEADER	32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence	17.0/25 ROCE 15.1% · OPM 30% 76% evidence	9.4/20 P/E 53.8× · PEG — 15% evidence	14.4/20 RS sector 26.6% · RS bench 57.6% · 1Y 126.5%12 of 12 weeks ahead 100% evidence
Exact sum: 32.4 + 17 + 9.4 + 14.4 = 73.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Wanbury LtdWANBURY	65.1/100Favorable setup81% evidence	FADING	19.9/35 Revenue 3.6% · PAT 30% · OPM change -5.2 pp 95% evidence	18.6/25 ROCE 30.8% · OPM 9.8% 95% evidence	14.3/20 P/E 15.4× · PEG — 50% evidence	12.3/20 RS sector 5.3% · RS bench 0% · 1Y 2.7%6 of 11 weeks ahead 70% evidence
Exact sum: 19.9 + 18.6 + 14.3 + 12.3 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Innova Captab LtdINNOVACAP	57.0/100Mixed-positive evidence100% evidence	LEADER	24.8/35 Revenue 34.4% · PAT 18.5% · OPM change 1 pp 100% evidence	13.2/25 ROCE 15% · OPM 16% 100% evidence	6.6/20 P/E 38.5× · PEG 4.06 100% evidence	12.4/20 RS sector 0.7% · RS bench 26.4% · 1Y 13%11 of 12 weeks ahead 100% evidence
Exact sum: 24.8 + 13.2 + 6.6 + 12.4 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Ind-Swift Laboratories LtdINDSWFTLAB	55.4/100Mixed-positive evidence87% evidence	BREAKING OUT	23.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence	6.0/25 ROCE 4.7% · OPM 17% 95% evidence	6.3/20 P/E 40.6× · PEG — 50% evidence	20.0/20 RS sector 74.8% · RS bench 116.5% · 1Y 206.8%11 of 12 weeks ahead 100% evidence
Exact sum: 23.1 + 6 + 6.3 + 20 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Jagsonpal Pharmaceuticals LtdJAGSNPHARM	53.1/100Mixed-positive evidence87% evidence	BREAKING OUT	15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence	18.9/25 ROCE 22.7% · OPM 21% 95% evidence	10.7/20 P/E 31.8× · PEG — 50% evidence	7.8/20 RS sector -14.7% · RS bench 7.6% · 1Y -11.3%11 of 12 weeks ahead 100% evidence
Exact sum: 15.7 + 18.9 + 10.7 + 7.8 = 53.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Aarti Drugs LtdAARTIDRUGS	47.5/100Mixed-negative evidence100% evidence	BREAKING OUT	17.7/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence	12.0/25 ROCE 11.9% · OPM 14% 100% evidence	12.3/20 P/E 19.7× · PEG 2.4 100% evidence	5.5/20 RS sector -21.6% · RS bench -0.6% · 1Y -15.3%6 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 12 + 12.3 + 5.5 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Beta Drugs LtdBETA	46.8/100Mixed-negative evidence76% evidence	BREAKING OUT	11.6/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence	18.4/25 ROCE 19.2% · OPM 22% 76% evidence	7.1/20 P/E 62× · PEG — 50% evidence	9.7/20 RS sector -17.9% · RS bench 51.5% · 1Y 47.6%10 of 10 weeks ahead 70% evidence
Exact sum: 11.6 + 18.4 + 7.1 + 9.7 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Fermenta Biotech LtdFERMENTA	45.2/100Mixed-negative evidence74% evidence	BREAKING OUT	5.0/35 Revenue -3.1% · PAT -44% · OPM change -5.9 pp 95% evidence	14.3/25 ROCE 20.6% · OPM 14.8% 95% evidence	10.8/20 P/E 24.2× · PEG — 15% evidence	15.1/20 RS sector 15.7% · RS bench 30.9% · 1Y 32.4%5 of 7 weeks ahead 70% evidence
Exact sum: 5 + 14.3 + 10.8 + 15.1 = 45.2 · Decision use: Price leads the evidence: RS versus the benchmark is 30.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9Anuh Pharma LtdANUHPHR	43.3/100Mixed-negative evidence87% evidence	ASLEEP	16.5/35 Revenue 9.7% · PAT -2.2% · OPM change 2 pp 95% evidence	12.9/25 ROCE 14.9% · OPM 8% 95% evidence	12.6/20 P/E 17.3× · PEG — 50% evidence	1.3/20 RS sector -26.4% · RS bench -6.5% · 1Y -16.5%0 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 12.9 + 12.6 + 1.3 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Gujarat Themis Biosyn LtdGUJTHEM	42.6/100Mixed-negative evidence93% evidence	ASLEEP	20.1/35 Revenue 16.1% · PAT 6.7% · OPM change 9 pp 100% evidence	15.6/25 ROCE 14.8% · OPM 48% 100% evidence	6.9/20 P/E 78× · PEG 2.55 65% evidence	0.0/20 RS sector -27.2% · RS bench -7.8% · 1Y 2.2%8 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 15.6 + 6.9 + 0 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Kopran LtdKOPRAN	41.4/100Mixed-negative evidence81% evidence	BREAKING OUT	14.5/35 Revenue 12% · PAT -28.4% · OPM change -0.2 pp 95% evidence	9.6/25 ROCE 6.7% · OPM 10.3% 95% evidence	8.1/20 P/E 36.8× · PEG — 50% evidence	9.2/20 RS sector -17.6% · RS bench 17.6% · 1Y 21.1%11 of 11 weeks ahead 70% evidence
Exact sum: 14.5 + 9.6 + 8.1 + 9.2 = 41.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Orchid Pharma LtdORCHPHARMA	36.7/100Mixed-negative evidence85% evidence	BREAKING OUT	17.4/35 Revenue 14.1% · PAT -80% · OPM change 6.8 pp 74% evidence	1.8/25 ROCE 1.7% · OPM 4.6% 100% evidence	8.5/20 P/E 552× · PEG 1.77 100% evidence	9.0/20 RS sector -19.8% · RS bench 35.1% · 1Y 38.5%11 of 11 weeks ahead 70% evidence
Exact sum: 17.4 + 1.8 + 8.5 + 9 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Aarti Pharmalabs LtdAARTIPHARM	35.1/100Mixed-negative evidence94% evidence	TURNING	10.2/35 Revenue 1.2% · PAT -20.2% · OPM change 1 pp 100% evidence	11.8/25 ROCE 10.7% · OPM 25% 100% evidence	3.3/20 P/E 35.9× · PEG 5.52 100% evidence	9.8/20 RS sector -10.7% · RS bench 12.3% · 1Y 0.6%1 of 10 weeks ahead 70% evidence
Exact sum: 10.2 + 11.8 + 3.3 + 9.8 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Themis Medicare LtdTHEMISMED	22.6/100Adverse evidence72% evidence	FADING	6.1/35 Revenue -12.9% · PAT 100% · OPM change -50 pp 71% evidence	2.5/25 ROCE 2.7% · OPM -60% 95% evidence	8.5/20 P/E 939.2× · PEG — 15% evidence	5.5/20 RS sector -20.6% · RS bench 0.1% · 1Y -6.4%10 of 12 weeks ahead 100% evidence
Exact sum: 6.1 + 2.5 + 8.5 + 5.5 = 22.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Showing 10 of 14 companies

05 · what price has already done

Market action

Ind-Swift Laboratories Ltd has the strongest one-year price move in Pharma - API at +206.8%. It also leads on Mansfield relative strength against NIFTY at +116.5%. 11 of 14 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · compare level, then change

Revenue Scale & Growth Durability

Aarti Drugs Ltd has the highest Revenue among the 14 Pharma - API companies compared here, at ₹2,678 crore. Aarti Pharmalabs Ltd is next at ₹1,969 crore. Ind-Swift Laboratories Ltd has the highest Revenue growth at 53.9%, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Aarti Drugs Ltd is the scale leader at ₹2,678 crore, 36% ahead of Aarti Pharmalabs Ltd. Ind-Swift Laboratories Ltd's growth is 53.9% from a ₹665 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderAarti Drugs Ltd · ₹2,678 crore

Gap36% versus #2 · Aarti Pharmalabs Ltd

Persistence6/8 recent comparable periods

Coverage14/14 companies · 229 observations

Investor read: Aarti Drugs Ltd is the scale benchmark; Ind-Swift Laboratories Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Aarti Drugs Ltd's growth falls below Ind-Swift Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1Aarti Drugs Ltd AARTIDRUGS₹2.7K Cr

2Aarti Pharmalabs Ltd AARTIPHARM₹2.0K Cr

3Innova Captab Ltd INNOVACAP₹1.7K Cr

4Orchid Pharma Ltd ORCHPHARMA₹1.1K Cr

5Anuh Pharma Ltd ANUHPHR⚠ unverified₹779 Cr

Revenue growthfastest growers

1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified54%

2Senores Pharmaceuticals Ltd SENORES51%

3Innova Captab Ltd INNOVACAP34%

4Gujarat Themis Biosyn Ltd GUJTHEM16%

5Orchid Pharma Ltd ORCHPHARMA14%

Revenue · company comparison

14/14 level · 14/14 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
Aarti Drugs Ltd AARTIDRUGS	₹703 Cr	19%	Jun 2026
Aarti Pharmalabs Ltd AARTIPHARM	₹536 Cr	39%	Jun 2026
Innova Captab Ltd INNOVACAP	₹471 Cr	34%	Jun 2026
Orchid Pharma Ltd ORCHPHARMA	₹304 Cr	16%	Jun 2026
Anuh Pharma Ltd ANUHPHR⚠ unverified	₹194 Cr	4.3%	Jun 2026
Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified	₹191 Cr	25%	Jun 2026
Senores Pharmaceuticals Ltd SENORES	₹180 Cr	30%	Jun 2026
Wanbury Ltd WANBURY⚠ unverified	₹166 Cr	1.5%	Jun 2026
Kopran Ltd KOPRAN⚠ unverified	₹154 Cr	14%	Jun 2026
Beta Drugs Ltd BETA	₹126 Cr	26%	Jun 2026
Fermenta Biotech Ltd FERMENTA⚠ unverified	₹122 Cr	-11%	Jun 2026
Themis Medicare Ltd THEMISMED⚠ unverified	₹87 Cr	-11%	Jun 2026
Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified	₹82 Cr	7.9%	Jun 2026
Gujarat Themis Biosyn Ltd GUJTHEM	₹44 Cr	22%	Jun 2026

Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021₹580 Cr

Dec 2021₹635 Cr

Mar 2022₹694 Cr

Jun 2022₹622 Cr

Sep 2022₹688 Cr

Dec 2022₹664 Cr

Mar 2023₹742 Cr

Jun 2023₹661 Cr

Sep 2023₹642 Cr

Dec 2023₹606 Cr

Mar 2024₹620 Cr

Jun 2024₹555 Cr

Sep 2024₹598 Cr

Dec 2024₹557 Cr

Mar 2025₹677 Cr

Jun 2025₹591 Cr

Sep 2025₹653 Cr

Dec 2025₹602 Cr

Mar 2026₹720 Cr

Jun 2026₹703 Cr

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021₹600 Cr

Mar 2022₹600 Cr

Jun 2022₹457 Cr

Sep 2022₹531 Cr

Dec 2022₹472 Cr

Mar 2023₹485 Cr

Jun 2023₹458 Cr

Sep 2023₹440 Cr

Dec 2023₹449 Cr

Mar 2024₹506 Cr

Jun 2024₹555 Cr

Sep 2024₹458 Cr

Dec 2024₹538 Cr

Mar 2025₹564 Cr

Jun 2025₹386 Cr

Sep 2025₹418 Cr

Dec 2025₹432 Cr

Mar 2026₹583 Cr

Jun 2026₹536 Cr

Beta Drugs Ltd · BETA

Sep 2021₹88 Cr

Dec 2021—

Mar 2022₹96 Cr

Jun 2022—

Sep 2022₹112 Cr

Dec 2022—

Mar 2023₹115 Cr

Jun 2023—

Sep 2023₹141 Cr

Dec 2023—

Mar 2024₹154 Cr

Jun 2024—

Sep 2024₹180 Cr

Dec 2024₹88 Cr

Mar 2025₹94 Cr

Jun 2025₹100 Cr

Sep 2025₹103 Cr

Dec 2025₹87 Cr

Mar 2026₹94 Cr

Jun 2026₹126 Cr

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹55 Cr

Mar 2023₹105 Cr

Jun 2023₹82 Cr

Sep 2023₹57 Cr

Dec 2023₹99 Cr

Mar 2024₹97 Cr

Jun 2024₹78 Cr

Sep 2024₹95 Cr

Dec 2024₹156 Cr

Mar 2025₹140 Cr

Jun 2025₹136 Cr

Sep 2025₹130 Cr

Dec 2025₹137 Cr

Mar 2026₹122 Cr

Jun 2026₹122 Cr

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021₹35 Cr

Dec 2021₹19 Cr

Mar 2022₹29 Cr

Jun 2022₹45 Cr

Sep 2022₹48 Cr

Dec 2022₹28 Cr

Mar 2023₹28 Cr

Jun 2023₹50 Cr

Sep 2023₹40 Cr

Dec 2023₹39 Cr

Mar 2024₹42 Cr

Jun 2024₹39 Cr

Sep 2024₹35 Cr

Dec 2024₹40 Cr

Mar 2025₹38 Cr

Jun 2025₹36 Cr

Sep 2025₹42 Cr

Dec 2025₹43 Cr

Mar 2026₹44 Cr

Jun 2026₹44 Cr

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹313 Cr

Mar 2023₹304 Cr

Jun 2023₹310 Cr

Sep 2023₹290 Cr

Dec 2023₹288 Cr

Mar 2024₹529 Cr

Jun 2024₹33 Cr

Sep 2024₹12 Cr

Dec 2024₹129 Cr

Mar 2025₹138 Cr

Jun 2025₹153 Cr

Sep 2025₹153 Cr

Dec 2025₹151 Cr

Mar 2026₹170 Cr

Jun 2026₹191 Cr

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022₹216 Cr

Jun 2022₹222 Cr

Sep 2022₹242 Cr

Dec 2022₹242 Cr

Mar 2023₹241 Cr

Jun 2023₹233 Cr

Sep 2023₹283 Cr

Dec 2023₹302 Cr

Mar 2024₹263 Cr

Jun 2024₹294 Cr

Sep 2024₹318 Cr

Dec 2024₹316 Cr

Mar 2025₹315 Cr

Jun 2025₹352 Cr

Sep 2025₹380 Cr

Dec 2025₹450 Cr

Mar 2026₹448 Cr

Jun 2026₹471 Cr

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹60 Cr

Mar 2023₹55 Cr

Jun 2023₹60 Cr

Sep 2023₹58 Cr

Dec 2023₹47 Cr

Mar 2024₹43 Cr

Jun 2024₹61 Cr

Sep 2024₹75 Cr

Dec 2024₹74 Cr

Mar 2025₹59 Cr

Jun 2025₹76 Cr

Sep 2025₹74 Cr

Dec 2025₹73 Cr

Mar 2026₹64 Cr

Jun 2026₹82 Cr

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹158 Cr

Mar 2023₹149 Cr

Jun 2023₹117 Cr

Sep 2023₹153 Cr

Dec 2023₹159 Cr

Mar 2024₹186 Cr

Jun 2024₹139 Cr

Sep 2024₹152 Cr

Dec 2024₹166 Cr

Mar 2025₹172 Cr

Jun 2025₹135 Cr

Sep 2025₹118 Cr

Dec 2025₹194 Cr

Mar 2026₹234 Cr

Jun 2026₹154 Cr

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021₹128 Cr

Dec 2021₹161 Cr

Mar 2022₹178 Cr

Jun 2022₹131 Cr

Sep 2022₹165 Cr

Dec 2022₹160 Cr

Mar 2023₹210 Cr

Jun 2023₹183 Cr

Sep 2023₹199 Cr

Dec 2023₹221 Cr

Mar 2024₹217 Cr

Jun 2024₹244 Cr

Sep 2024₹223 Cr

Dec 2024₹217 Cr

Mar 2025₹237 Cr

Jun 2025₹263 Cr

Sep 2025₹194 Cr

Dec 2025₹207 Cr

Mar 2026₹368 Cr

Jun 2026₹304 Cr

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023₹79 Cr

Mar 2024₹102 Cr

Jun 2024₹80 Cr

Sep 2024₹101 Cr

Dec 2024₹103 Cr

Mar 2025₹114 Cr

Jun 2025₹138 Cr

Sep 2025₹162 Cr

Dec 2025₹171 Cr

Mar 2026₹175 Cr

Jun 2026₹180 Cr

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹89 Cr

Mar 2023₹80 Cr

Jun 2023₹97 Cr

Sep 2023₹105 Cr

Dec 2023₹83 Cr

Mar 2024₹98 Cr

Jun 2024₹123 Cr

Sep 2024₹117 Cr

Dec 2024₹94 Cr

Mar 2025₹72 Cr

Jun 2025₹98 Cr

Sep 2025₹78 Cr

Dec 2025₹90 Cr

Mar 2026₹77 Cr

Jun 2026₹87 Cr

Revenue growth · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20227.2%

Sep 202219%

Dec 20224.6%

Mar 20236.9%

Jun 20236.3%

Sep 2023-6.7%

Dec 2023-8.7%

Mar 2024-16%

Jun 2024-16%

Sep 2024-6.9%

Dec 2024-8.1%

Mar 20259.2%

Jun 20256.5%

Sep 20259.2%

Dec 20258.1%

Mar 20266.4%

Jun 202619%

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022-21%

Mar 2023-19%

Jun 20230.2%

Sep 2023-17%

Dec 2023-4.9%

Mar 20244.3%

Jun 202421%

Sep 20244.1%

Dec 202420%

Mar 202511%

Jun 2025-30%

Sep 2025-8.7%

Dec 2025-20%

Mar 20263.4%

Jun 202639%

Beta Drugs Ltd · BETA

Sep 202173%

Dec 2021—

Mar 202248%

Jun 2022—

Sep 202227%

Dec 2022—

Mar 202320%

Jun 2023—

Sep 202326%

Dec 2023—

Mar 202434%

Jun 2024—

Sep 202428%

Dec 2024—

Mar 2025-39%

Jun 2025—

Sep 2025-43%

Dec 2025-1.1%

Mar 20260.0%

Jun 202626%

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202380%

Mar 2024-7.3%

Jun 2024-5.2%

Sep 202467%

Dec 202458%

Mar 202544%

Jun 202574%

Sep 202537%

Dec 2025-12%

Mar 2026-13%

Jun 2026-11%

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202241%

Sep 202237%

Dec 202247%

Mar 2023-3.5%

Jun 202311%

Sep 2023-17%

Dec 202339%

Mar 202450%

Jun 2024-22%

Sep 2024-13%

Dec 20242.6%

Mar 2025-9.5%

Jun 2025-7.7%

Sep 202520%

Dec 20257.5%

Mar 202616%

Jun 202622%

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-7.9%

Mar 202474%

Jun 2024-89%

Sep 2024-96%

Dec 2024-55%

Mar 2025-74%

Jun 2025364%

Sep 20251,175%

Dec 202517%

Mar 202623%

Jun 202625%

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 202312%

Jun 20235.0%

Sep 202317%

Dec 202325%

Mar 20249.1%

Jun 202426%

Sep 202412%

Dec 20244.6%

Mar 202520%

Jun 202520%

Sep 202520%

Dec 202542%

Mar 202642%

Jun 202634%

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-22%

Mar 2024-22%

Jun 20241.7%

Sep 202429%

Dec 202457%

Mar 202537%

Jun 202525%

Sep 2025-1.3%

Dec 2025-1.4%

Mar 20268.5%

Jun 20267.9%

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20230.6%

Mar 202425%

Jun 202419%

Sep 2024-0.7%

Dec 20244.6%

Mar 2025-7.4%

Jun 2025-3.0%

Sep 2025-22%

Dec 202517%

Mar 202636%

Jun 202614%

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202242%

Sep 202229%

Dec 2022-0.6%

Mar 202318%

Jun 202340%

Sep 202320%

Dec 202338%

Mar 20243.4%

Jun 202434%

Sep 202412%

Dec 2024-1.5%

Mar 20259.4%

Jun 20257.7%

Sep 2025-13%

Dec 2025-4.6%

Mar 202655%

Jun 202616%

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 202430%

Mar 202512%

Jun 202573%

Sep 202560%

Dec 202566%

Mar 202654%

Jun 202630%

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-6.7%

Mar 202422%

Jun 202427%

Sep 202411%

Dec 202413%

Mar 2025-27%

Jun 2025-20%

Sep 2025-33%

Dec 2025-4.3%

Mar 20266.9%

Jun 2026-11%

07 · compare level, then change

Operating Economics & Margin Trend

Gujarat Themis Biosyn Ltd has the highest OPM among the 14 Pharma - API companies compared here, at 48%. Senores Pharmaceuticals Ltd is next at 30%. Ind-Swift Laboratories Ltd has the highest Margin change at +14.6 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Gujarat Themis Biosyn Ltd leads opm at 48%; Ind-Swift Laboratories Ltd leads margin change at +14.6 percentage points.

LeaderGujarat Themis Biosyn Ltd · 48%

Gap60% versus #2 · Senores Pharmaceuticals Ltd

Persistence6/8 recent comparable periods

Coverage14/14 companies · 262 observations

Investor read: Gujarat Themis Biosyn Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Gujarat Themis Biosyn Ltd GUJTHEM48%

2Senores Pharmaceuticals Ltd SENORES30%

3Aarti Pharmalabs Ltd AARTIPHARM25%

4Beta Drugs Ltd BETA22%

5Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified21%

Margin changefastest expanders

1Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified+14.6 pp

2Gujarat Themis Biosyn Ltd GUJTHEM+9.0 pp

3Orchid Pharma Ltd ORCHPHARMA+6.8 pp

4Senores Pharmaceuticals Ltd SENORES+5.0 pp

5Anuh Pharma Ltd ANUHPHR⚠ unverified+2.0 pp

Operating margin · company comparison

14/14 level · 14/14 change

All-company data · latest reported quarter

Company	OPM	Margin change	Reported
Gujarat Themis Biosyn Ltd GUJTHEM	48%	+9.0 pp	Jun 2026
Senores Pharmaceuticals Ltd SENORES	30%	+5.0 pp	Jun 2026
Aarti Pharmalabs Ltd AARTIPHARM	25%	+1.0 pp	Jun 2026
Beta Drugs Ltd BETA	22%	+2.0 pp	Jun 2026
Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified	21%	+2.0 pp	Jun 2026
Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified	17%	+14.6 pp	Jun 2026
Innova Captab Ltd INNOVACAP	16%	+1.0 pp	Jun 2026
Fermenta Biotech Ltd FERMENTA⚠ unverified	15%	−5.9 pp	Jun 2026
Aarti Drugs Ltd AARTIDRUGS	14%	+1.0 pp	Jun 2026
Kopran Ltd KOPRAN⚠ unverified	10%	−0.2 pp	Jun 2026
Wanbury Ltd WANBURY⚠ unverified	9.8%	−5.2 pp	Jun 2026
Anuh Pharma Ltd ANUHPHR⚠ unverified	8.0%	+2.0 pp	Jun 2026
Orchid Pharma Ltd ORCHPHARMA	4.6%	+6.8 pp	Jun 2026
Themis Medicare Ltd THEMISMED⚠ unverified	-60%	−50.0 pp	Jun 2026

Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 202113%

Dec 202114%

Mar 202212%

Jun 202211%

Sep 202211%

Dec 202211%

Mar 202313%

Jun 202313%

Sep 202312%

Dec 202312%

Mar 202414%

Jun 202412%

Sep 202411%

Dec 202411%

Mar 202514%

Jun 202513%

Sep 202513%

Dec 20259.0%

Mar 202613%

Jun 202614%

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 202114%

Mar 202216%

Jun 202219%

Sep 202217%

Dec 202218%

Mar 202316%

Jun 202319%

Sep 202320%

Dec 202321%

Mar 202423%

Jun 202417%

Sep 202420%

Dec 202424%

Mar 202526%

Jun 202524%

Sep 202518%

Dec 202524%

Mar 202619%

Jun 202625%

Beta Drugs Ltd · BETA

Sep 202123%

Dec 2021—

Mar 202224%

Jun 2022—

Sep 202224%

Dec 2022—

Mar 202323%

Jun 2023—

Sep 202323%

Dec 2023—

Mar 202418%

Jun 2024—

Sep 202422%

Dec 202421%

Mar 202518%

Jun 202520%

Sep 202521%

Dec 202519%

Mar 202619%

Jun 202622%

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 202116%

Dec 20212.4%

Mar 202218%

Jun 20225.3%

Sep 20223.4%

Dec 2022-18%

Mar 202318%

Jun 202313%

Sep 2023-24%

Dec 202325%

Mar 20245.5%

Jun 20241.0%

Sep 202420%

Dec 202434%

Mar 202526%

Jun 202521%

Sep 202520%

Dec 202518%

Mar 202616%

Jun 202615%

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 202153%

Dec 202153%

Mar 202245%

Jun 202251%

Sep 202251%

Dec 202243%

Mar 202352%

Jun 202347%

Sep 202342%

Dec 202346%

Mar 202450%

Jun 202448%

Sep 202444%

Dec 202448%

Mar 202542%

Jun 202539%

Sep 202549%

Dec 202549%

Mar 202644%

Jun 202648%

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 202124%

Dec 202121%

Mar 202212%

Jun 202219%

Sep 202219%

Dec 202217%

Mar 202321%

Jun 202319%

Sep 202323%

Dec 202318%

Mar 202417%

Jun 2024-29%

Sep 2024-99%

Dec 2024-5.0%

Mar 2025-7.0%

Jun 20252.4%

Sep 20251.0%

Dec 20252.8%

Mar 202612%

Jun 202617%

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 20227.9%

Jun 202211%

Sep 202213%

Dec 202214%

Mar 202311%

Jun 202313%

Sep 202314%

Dec 202315%

Mar 202414%

Jun 202414%

Sep 202416%

Dec 202415%

Mar 202515%

Jun 202515%

Sep 202514%

Dec 202515%

Mar 202615%

Jun 202616%

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 202116%

Dec 202110%

Mar 20221.5%

Jun 202212%

Sep 202221%

Dec 202214%

Mar 20239.8%

Jun 202314%

Sep 202314%

Dec 20237.0%

Mar 20246.0%

Jun 202417%

Sep 202422%

Dec 202421%

Mar 202515%

Jun 202519%

Sep 202522%

Dec 202522%

Mar 202617%

Jun 202621%

Kopran Ltd · KOPRAN⚠ unverified

Sep 202119%

Dec 202121%

Mar 202218%

Jun 202210%

Sep 20228.7%

Dec 20227.8%

Mar 20238.0%

Jun 20235.4%

Sep 202315%

Dec 202315%

Mar 202412%

Jun 202413%

Sep 20249.7%

Dec 202412%

Mar 20259.9%

Jun 202510%

Sep 2025-4.5%

Dec 20259.1%

Mar 202614%

Jun 202610%

Orchid Pharma Ltd · ORCHPHARMA

Sep 20218.9%

Dec 20218.7%

Mar 202214%

Jun 20229.5%

Sep 202211%

Dec 20229.0%

Mar 202319%

Jun 202312%

Sep 202312%

Dec 202316%

Mar 202413%

Jun 202413%

Sep 202414%

Dec 202412%

Mar 202512%

Jun 2025-2.2%

Sep 2025-0.8%

Dec 20250.8%

Mar 20268.2%

Jun 20264.6%

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202319%

Mar 202422%

Jun 202427%

Sep 202423%

Dec 202425%

Mar 202517%

Jun 202525%

Sep 202531%

Dec 202529%

Mar 202627%

Jun 202630%

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 202122%

Dec 202118%

Mar 202218%

Jun 202222%

Sep 202223%

Dec 202217%

Mar 202313%

Jun 202322%

Sep 202312%

Dec 202310%

Mar 202410%

Jun 202424%

Sep 202415%

Dec 20246.0%

Mar 2025-11%

Jun 2025-10%

Sep 2025-4.0%

Dec 202511%

Mar 20264.9%

Jun 2026-60%

Margin change · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021−7.4 pp

Dec 2021−5.8 pp

Mar 2022−3.7 pp

Jun 2022−3.0 pp

Sep 2022−1.9 pp

Dec 2022−3.2 pp

Mar 2023+0.6 pp

Jun 2023+2.2 pp

Sep 2023+1.2 pp

Dec 2023+1.0 pp

Mar 2024+1.0 pp

Jun 2024−1.0 pp

Sep 2024−1.0 pp

Dec 2024−1.0 pp

Mar 20250.0 pp

Jun 2025+1.0 pp

Sep 2025+2.0 pp

Dec 2025−2.0 pp

Mar 2026−1.0 pp

Jun 2026+1.0 pp

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022+4.3 pp

Mar 2023−0.4 pp

Jun 2023+0.2 pp

Sep 2023+3.1 pp

Dec 2023+3.0 pp

Mar 2024+7.0 pp

Jun 2024−2.0 pp

Sep 20240.0 pp

Dec 2024+3.0 pp

Mar 2025+3.0 pp

Jun 2025+7.0 pp

Sep 2025−2.0 pp

Dec 20250.0 pp

Mar 2026−7.0 pp

Jun 2026+1.0 pp

Beta Drugs Ltd · BETA

Sep 2021+2.0 pp

Dec 2021—

Mar 2022+2.0 pp

Jun 2022—

Sep 2022+1.0 pp

Dec 2022—

Mar 2023−1.0 pp

Jun 2023—

Sep 2023−1.0 pp

Dec 2023—

Mar 2024−5.0 pp

Jun 2024—

Sep 2024−1.0 pp

Dec 2024—

Mar 20250.0 pp

Jun 2025—

Sep 2025−1.0 pp

Dec 2025−2.0 pp

Mar 2026+1.0 pp

Jun 2026+2.0 pp

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021−13.1 pp

Dec 2021−22.3 pp

Mar 2022+8.2 pp

Jun 2022−18.2 pp

Sep 2022−12.4 pp

Dec 2022−20.4 pp

Mar 2023−0.5 pp

Jun 2023+7.9 pp

Sep 2023−27.8 pp

Dec 2023+43.4 pp

Mar 2024−12.5 pp

Jun 2024−12.2 pp

Sep 2024+44.2 pp

Dec 2024+8.7 pp

Mar 2025+20.9 pp

Jun 2025+19.7 pp

Sep 2025+0.7 pp

Dec 2025−15.9 pp

Mar 2026−10.0 pp

Jun 2026−5.9 pp

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021−1.6 pp

Dec 2021+8.9 pp

Mar 2022+9.9 pp

Jun 2022−0.9 pp

Sep 2022−1.5 pp

Dec 2022−9.7 pp

Mar 2023+6.5 pp

Jun 2023−3.7 pp

Sep 2023−9.2 pp

Dec 2023+3.0 pp

Mar 2024−2.0 pp

Jun 2024+1.0 pp

Sep 2024+2.0 pp

Dec 2024+2.0 pp

Mar 2025−8.0 pp

Jun 2025−9.0 pp

Sep 2025+5.0 pp

Dec 2025+1.0 pp

Mar 2026+2.0 pp

Jun 2026+9.0 pp

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021+2.2 pp

Dec 2021−0.2 pp

Mar 2022−6.4 pp

Jun 2022−1.6 pp

Sep 2022−4.9 pp

Dec 2022−4.1 pp

Mar 2023+9.0 pp

Jun 2023+0.1 pp

Sep 2023+4.1 pp

Dec 2023+0.8 pp

Mar 2024−4.0 pp

Jun 2024−48.0 pp

Sep 2024−122.0 pp

Dec 2024−23.0 pp

Mar 2025−24.0 pp

Jun 2025+31.4 pp

Sep 2025+100.0 pp

Dec 2025+7.8 pp

Mar 2026+19.0 pp

Jun 2026+14.6 pp

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023+3.1 pp

Jun 2023+2.3 pp

Sep 2023+1.2 pp

Dec 2023+1.0 pp

Mar 2024+3.0 pp

Jun 2024+1.0 pp

Sep 2024+2.0 pp

Dec 20240.0 pp

Mar 2025+1.0 pp

Jun 2025+1.0 pp

Sep 2025−2.0 pp

Dec 20250.0 pp

Mar 20260.0 pp

Jun 2026+1.0 pp

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021+7.2 pp

Dec 2021−1.1 pp

Mar 2022−10.4 pp

Jun 2022−5.3 pp

Sep 2022+5.5 pp

Dec 2022+3.7 pp

Mar 2023+8.3 pp

Jun 2023+2.2 pp

Sep 2023−7.3 pp

Dec 2023−7.0 pp

Mar 2024−3.8 pp

Jun 2024+3.0 pp

Sep 2024+8.0 pp

Dec 2024+14.0 pp

Mar 2025+9.0 pp

Jun 2025+2.0 pp

Sep 20250.0 pp

Dec 2025+1.0 pp

Mar 2026+2.0 pp

Jun 2026+2.0 pp

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021+1.0 pp

Dec 2021+1.7 pp

Mar 2022+4.4 pp

Jun 2022−1.9 pp

Sep 2022−10.2 pp

Dec 2022−12.8 pp

Mar 2023−10.2 pp

Jun 2023−5.1 pp

Sep 2023+6.3 pp

Dec 2023+7.0 pp

Mar 2024+3.7 pp

Jun 2024+7.6 pp

Sep 2024−5.2 pp

Dec 2024−2.9 pp

Mar 2025−1.7 pp

Jun 2025−2.6 pp

Sep 2025−14.2 pp

Dec 2025−2.8 pp

Mar 2026+4.2 pp

Jun 2026−0.2 pp

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021−7.7 pp

Dec 2021+13.5 pp

Mar 2022+17.6 pp

Jun 2022+12.8 pp

Sep 2022+1.9 pp

Dec 2022+0.3 pp

Mar 2023+4.5 pp

Jun 2023+2.6 pp

Sep 2023+0.9 pp

Dec 2023+7.0 pp

Mar 2024−5.7 pp

Jun 2024+1.2 pp

Sep 2024+1.9 pp

Dec 2024−3.9 pp

Mar 2025−1.5 pp

Jun 2025−15.4 pp

Sep 2025−14.4 pp

Dec 2025−11.4 pp

Mar 2026−3.6 pp

Jun 2026+6.8 pp

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024+6.0 pp

Mar 2025−5.0 pp

Jun 2025−2.0 pp

Sep 2025+8.0 pp

Dec 2025+4.0 pp

Mar 2026+10.0 pp

Jun 2026+5.0 pp

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021+4.2 pp

Dec 2021−5.0 pp

Mar 2022−1.8 pp

Jun 2022−14.4 pp

Sep 2022+1.6 pp

Dec 2022−1.2 pp

Mar 2023−5.0 pp

Jun 2023+0.4 pp

Sep 2023−11.5 pp

Dec 2023−7.0 pp

Mar 2024−3.1 pp

Jun 2024+2.0 pp

Sep 2024+3.0 pp

Dec 2024−4.0 pp

Mar 2025−21.0 pp

Jun 2025−34.0 pp

Sep 2025−19.0 pp

Dec 2025+5.0 pp

Mar 2026+15.9 pp

Jun 2026−50.0 pp

08 · compare level, then change

Profit Scale & Acceleration

Aarti Pharmalabs Ltd has the highest Net profit among the 14 Pharma - API companies compared here, at ₹213 crore. Aarti Drugs Ltd is next at ₹191 crore. Senores Pharmaceuticals Ltd has the highest Profit growth at 92.7%, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Aarti Pharmalabs Ltd leads with ₹213 crore of TTM profit, 11.5% above Aarti Drugs Ltd. Senores Pharmaceuticals Ltd shows 92.7% growth from a ₹131 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderAarti Pharmalabs Ltd · ₹213 crore

Gap11.5% versus #2 · Aarti Drugs Ltd

Persistence4/8 recent comparable periods

Coverage14/14 companies · 230 observations

Investor read: Aarti Pharmalabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1Aarti Pharmalabs Ltd AARTIPHARM₹213 Cr

2Aarti Drugs Ltd AARTIDRUGS₹191 Cr

3Innova Captab Ltd INNOVACAP₹154 Cr

4Senores Pharmaceuticals Ltd SENORES₹131 Cr

5Fermenta Biotech Ltd FERMENTA⚠ unverified₹58 Cr

Profit growthfastest growers

1Senores Pharmaceuticals Ltd SENORES93%

2Wanbury Ltd WANBURY⚠ unverified30%

3Innova Captab Ltd INNOVACAP19%

4Gujarat Themis Biosyn Ltd GUJTHEM6.7%

5Aarti Drugs Ltd AARTIDRUGS1.1%

Net profit · company comparison

14/14 level · 12/14 change

All-company data · latest reported quarter

Company	Net profit	Profit growth	Reported
Aarti Pharmalabs Ltd AARTIPHARM	₹76 Cr	52%	Jun 2026
Aarti Drugs Ltd AARTIDRUGS	₹50 Cr	-7.4%	Jun 2026
Innova Captab Ltd INNOVACAP	₹44 Cr	42%	Jun 2026
Senores Pharmaceuticals Ltd SENORES	₹30 Cr	43%	Jun 2026
Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified	₹25 Cr	178%	Jun 2026
Themis Medicare Ltd THEMISMED⚠ unverified	₹25 Cr	900%	Jun 2026
Beta Drugs Ltd BETA	₹16 Cr	33%	Jun 2026
Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified	₹13 Cr	18%	Jun 2026
Gujarat Themis Biosyn Ltd GUJTHEM	₹11 Cr	22%	Jun 2026
Anuh Pharma Ltd ANUHPHR⚠ unverified	₹11 Cr	38%	Jun 2026
Fermenta Biotech Ltd FERMENTA⚠ unverified	₹10 Cr	-56%	Jun 2026
Kopran Ltd KOPRAN⚠ unverified	₹7 Cr	-10%	Jun 2026
Wanbury Ltd WANBURY⚠ unverified	₹3 Cr	-76%	Jun 2026
Orchid Pharma Ltd ORCHPHARMA	₹3 Cr	16%	Jun 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021₹43 Cr

Dec 2021₹58 Cr

Mar 2022₹55 Cr

Jun 2022₹35 Cr

Sep 2022₹39 Cr

Dec 2022₹37 Cr

Mar 2023₹56 Cr

Jun 2023₹48 Cr

Sep 2023₹40 Cr

Dec 2023₹37 Cr

Mar 2024₹47 Cr

Jun 2024₹33 Cr

Sep 2024₹35 Cr

Dec 2024₹37 Cr

Mar 2025₹63 Cr

Jun 2025₹54 Cr

Sep 2025₹45 Cr

Dec 2025₹41 Cr

Mar 2026₹55 Cr

Jun 2026₹50 Cr

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021₹0 Cr

Dec 2021₹61 Cr

Mar 2022₹61 Cr

Jun 2022₹52 Cr

Sep 2022₹51 Cr

Dec 2022₹48 Cr

Mar 2023₹43 Cr

Jun 2023₹47 Cr

Sep 2023₹52 Cr

Dec 2023₹53 Cr

Mar 2024₹65 Cr

Jun 2024₹55 Cr

Sep 2024₹55 Cr

Dec 2024₹74 Cr

Mar 2025₹88 Cr

Jun 2025₹50 Cr

Sep 2025₹28 Cr

Dec 2025₹48 Cr

Mar 2026₹61 Cr

Jun 2026₹76 Cr

Beta Drugs Ltd · BETA

Sep 2021₹12 Cr

Dec 2021—

Mar 2022₹13 Cr

Jun 2022—

Sep 2022₹16 Cr

Dec 2022—

Mar 2023₹15 Cr

Jun 2023—

Sep 2023₹20 Cr

Dec 2023—

Mar 2024₹17 Cr

Jun 2024—

Sep 2024₹24 Cr

Dec 2024₹9 Cr

Mar 2025₹9 Cr

Jun 2025₹12 Cr

Sep 2025₹12 Cr

Dec 2025₹9 Cr

Mar 2026₹9 Cr

Jun 2026₹16 Cr

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹-38 Cr

Mar 2023₹-5 Cr

Jun 2023₹2 Cr

Sep 2023₹-29 Cr

Dec 2023₹10 Cr

Mar 2024₹-7 Cr

Jun 2024₹-6 Cr

Sep 2024₹11 Cr

Dec 2024₹38 Cr

Mar 2025₹33 Cr

Jun 2025₹22 Cr

Sep 2025₹18 Cr

Dec 2025₹12 Cr

Mar 2026₹19 Cr

Jun 2026₹10 Cr

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021₹14 Cr

Dec 2021₹7 Cr

Mar 2022₹10 Cr

Jun 2022₹18 Cr

Sep 2022₹19 Cr

Dec 2022₹10 Cr

Mar 2023₹12 Cr

Jun 2023₹18 Cr

Sep 2023₹13 Cr

Dec 2023₹13 Cr

Mar 2024₹16 Cr

Jun 2024₹13 Cr

Sep 2024₹11 Cr

Dec 2024₹13 Cr

Mar 2025₹12 Cr

Jun 2025₹9 Cr

Sep 2025₹14 Cr

Dec 2025₹12 Cr

Mar 2026₹11 Cr

Jun 2026₹11 Cr

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹28 Cr

Mar 2023₹-25 Cr

Jun 2023₹17 Cr

Sep 2023₹32 Cr

Dec 2023₹19 Cr

Mar 2024₹494 Cr

Jun 2024₹1 Cr

Sep 2024₹0 Cr

Dec 2024₹-5 Cr

Mar 2025₹222 Cr

Jun 2025₹9 Cr

Sep 2025₹8 Cr

Dec 2025₹10 Cr

Mar 2026₹15 Cr

Jun 2026₹25 Cr

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022₹13 Cr

Jun 2022₹16 Cr

Sep 2022₹19 Cr

Dec 2022₹20 Cr

Mar 2023₹17 Cr

Jun 2023₹18 Cr

Sep 2023₹23 Cr

Dec 2023₹25 Cr

Mar 2024₹29 Cr

Jun 2024₹29 Cr

Sep 2024₹35 Cr

Dec 2024₹34 Cr

Mar 2025₹30 Cr

Jun 2025₹31 Cr

Sep 2025₹30 Cr

Dec 2025₹42 Cr

Mar 2026₹38 Cr

Jun 2026₹44 Cr

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹8 Cr

Mar 2023₹6 Cr

Jun 2023₹7 Cr

Sep 2023₹7 Cr

Dec 2023₹4 Cr

Mar 2024₹4 Cr

Jun 2024₹5 Cr

Sep 2024₹11 Cr

Dec 2024₹32 Cr

Mar 2025₹7 Cr

Jun 2025₹11 Cr

Sep 2025₹13 Cr

Dec 2025₹11 Cr

Mar 2026₹9 Cr

Jun 2026₹13 Cr

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹7 Cr

Mar 2023₹8 Cr

Jun 2023₹3 Cr

Sep 2023₹14 Cr

Dec 2023₹16 Cr

Mar 2024₹19 Cr

Jun 2024₹11 Cr

Sep 2024₹7 Cr

Dec 2024₹10 Cr

Mar 2025₹10 Cr

Jun 2025₹7 Cr

Sep 2025₹-10 Cr

Dec 2025₹9 Cr

Mar 2026₹19 Cr

Jun 2026₹7 Cr

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021₹49 Cr

Dec 2021₹-14 Cr

Mar 2022₹-7 Cr

Jun 2022₹-15 Cr

Sep 2022₹-5 Cr

Dec 2022₹8 Cr

Mar 2023₹59 Cr

Jun 2023₹9 Cr

Sep 2023₹20 Cr

Dec 2023₹29 Cr

Mar 2024₹33 Cr

Jun 2024₹29 Cr

Sep 2024₹27 Cr

Dec 2024₹21 Cr

Mar 2025₹22 Cr

Jun 2025₹-6 Cr

Sep 2025₹-6 Cr

Dec 2025₹-13 Cr

Mar 2026₹26 Cr

Jun 2026₹3 Cr

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023₹7 Cr

Mar 2024₹14 Cr

Jun 2024₹11 Cr

Sep 2024₹13 Cr

Dec 2024₹16 Cr

Mar 2025₹18 Cr

Jun 2025₹21 Cr

Sep 2025₹30 Cr

Dec 2025₹34 Cr

Mar 2026₹37 Cr

Jun 2026₹30 Cr

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022₹13 Cr

Mar 2023₹8 Cr

Jun 2023₹18 Cr

Sep 2023₹11 Cr

Dec 2023₹7 Cr

Mar 2024₹7 Cr

Jun 2024₹25 Cr

Sep 2024₹14 Cr

Dec 2024₹1 Cr

Mar 2025₹-10 Cr

Jun 2025₹-14 Cr

Sep 2025₹-4 Cr

Dec 2025₹10 Cr

Mar 2026₹9 Cr

Jun 2026₹25 Cr

Profit growth · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-29%

Sep 2022-9.3%

Dec 2022-36%

Mar 20231.8%

Jun 202337%

Sep 20232.6%

Dec 20230.0%

Mar 2024-16%

Jun 2024-31%

Sep 2024-13%

Dec 20240.0%

Mar 202534%

Jun 202564%

Sep 202529%

Dec 202511%

Mar 2026-13%

Jun 2026-7.4%

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022-21%

Mar 2023-30%

Jun 2023-9.6%

Sep 20232.0%

Dec 202310%

Mar 202451%

Jun 202417%

Sep 20245.8%

Dec 202440%

Mar 202535%

Jun 2025-9.1%

Sep 2025-49%

Dec 2025-35%

Mar 2026-31%

Jun 202652%

Beta Drugs Ltd · BETA

Sep 2021140%

Dec 2021—

Mar 202286%

Jun 2022—

Sep 202233%

Dec 2022—

Mar 202315%

Jun 2023—

Sep 202325%

Dec 2023—

Mar 202413%

Jun 2024—

Sep 202420%

Dec 2024—

Mar 2025-47%

Jun 2025—

Sep 2025-50%

Dec 20250.0%

Mar 20260.0%

Jun 202633%

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024-368%

Sep 2024—

Dec 2024279%

Mar 2025—

Jun 2025—

Sep 202562%

Dec 2025-68%

Mar 2026-44%

Jun 2026-56%

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202238%

Sep 202236%

Dec 202243%

Mar 202320%

Jun 20230.0%

Sep 2023-32%

Dec 202330%

Mar 202433%

Jun 2024-28%

Sep 2024-15%

Dec 20240.0%

Mar 2025-25%

Jun 2025-31%

Sep 202527%

Dec 2025-7.7%

Mar 2026-8.3%

Jun 202622%

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-31%

Mar 2024—

Jun 2024-94%

Sep 2024-100%

Dec 2024-126%

Mar 2025-55%

Jun 2025800%

Sep 2025—

Dec 2025—

Mar 2026-93%

Jun 2026178%

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 202331%

Jun 202313%

Sep 202321%

Dec 202325%

Mar 202471%

Jun 202461%

Sep 202452%

Dec 202436%

Mar 20253.5%

Jun 20256.9%

Sep 2025-14%

Dec 202524%

Mar 202627%

Jun 202642%

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-50%

Mar 2024-29%

Jun 2024-29%

Sep 202457%

Dec 2024700%

Mar 202575%

Jun 2025120%

Sep 202518%

Dec 2025-66%

Mar 202629%

Jun 202618%

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023127%

Mar 2024133%

Jun 2024301%

Sep 2024-46%

Dec 2024-34%

Mar 2025-48%

Jun 2025-33%

Sep 2025-234%

Dec 2025-10%

Mar 202695%

Jun 2026-10%

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022-110%

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023268%

Mar 2024-44%

Jun 2024212%

Sep 202438%

Dec 2024-29%

Mar 2025-32%

Jun 2025-119%

Sep 2025-121%

Dec 2025-161%

Mar 202616%

Jun 2026—

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024129%

Mar 202529%

Jun 202591%

Sep 2025131%

Dec 2025113%

Mar 2026106%

Jun 202643%

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-46%

Mar 2024-17%

Jun 202439%

Sep 202427%

Dec 2024-86%

Mar 2025-243%

Jun 2025-156%

Sep 2025-129%

Dec 2025900%

Mar 2026—

Jun 2026—

09 · compare level, then change

Return On Capital Employed

Wanbury Ltd has the highest ROCE among the 14 Pharma - API companies compared here, at 30.8%. Jagsonpal Pharmaceuticals Ltd is next at 22.7%. Senores Pharmaceuticals Ltd has the highest ROCE change at +4 percentage points, so level and change sit with different companies. 14 of 14 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Wanbury Ltd leads ROCE at 30.8%, 8.1 percentage points above Jagsonpal Pharmaceuticals Ltd. Senores Pharmaceuticals Ltd has the strongest latest improvement at +4 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderWanbury Ltd · 30.8%

Gap35.7% versus #2 · Jagsonpal Pharmaceuticals Ltd

Persistence2/8 recent comparable periods

Coverage14/14 companies · 179 observations

Investor read: Wanbury Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1Wanbury Ltd WANBURY⚠ unverified31%

2Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified23%

3Fermenta Biotech Ltd FERMENTA⚠ unverified21%

4Beta Drugs Ltd BETA19%

5Senores Pharmaceuticals Ltd SENORES15%

ROCE changefastest improvers

1Senores Pharmaceuticals Ltd SENORES+4.0 pp

2Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified+3.5 pp

3Wanbury Ltd WANBURY⚠ unverified+2.4 pp

4Innova Captab Ltd INNOVACAP+0.4 pp

5Kopran Ltd KOPRAN⚠ unverified+0.1 pp

Return on capital · company comparison

14/14 level · 14/14 change

Withheld from this chart: Senores Pharmaceuticals Ltd (SENORES) — its two data sources disagree by up to 13% on reported income across 10 comparable periods, so its derived ratios are withheld; Beta Drugs Ltd (BETA) — its two data sources disagree by up to 50% on reported income across 11 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter

Company	ROCE	ROCE change	Reported
Wanbury Ltd WANBURY⚠ unverified	29%	+2.4 pp	Jun 2026
Fermenta Biotech Ltd FERMENTA⚠ unverified	18%	−4.7 pp	Jun 2026
Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified	17%	−0.1 pp	Jun 2026
Gujarat Themis Biosyn Ltd GUJTHEM	15%	−8.1 pp	Jun 2026
Innova Captab Ltd INNOVACAP	14%	+0.4 pp	Jun 2026
Anuh Pharma Ltd ANUHPHR⚠ unverified	13%	−3.3 pp	Jun 2026
Aarti Drugs Ltd AARTIDRUGS	13%	−0.4 pp	Jun 2026
Aarti Pharmalabs Ltd AARTIPHARM	12%	−5.1 pp	Jun 2026
Kopran Ltd KOPRAN⚠ unverified	11%	+0.1 pp	Jun 2026
Orchid Pharma Ltd ORCHPHARMA	0.3%	−5.6 pp	Jun 2026
Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified	-0.1%	+3.5 pp	Jun 2026
Themis Medicare Ltd THEMISMED⚠ unverified	-2.3%	−11.4 pp	Jun 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

Aarti Drugs Ltd · AARTIDRUGS

Sep 202126%

Dec 2021—

Mar 202223%

Jun 2022—

Sep 202221%

Dec 2022—

Mar 202317%

Jun 2023—

Sep 202318%

Dec 202320%

Mar 202416%

Jun 202416%

Sep 202414%

Dec 202415%

Mar 202513%

Jun 202515%

Sep 202514%

Dec 202514%

Mar 202613%

Jun 2026—

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021-7.3%

Dec 20215.6%

Mar 202211%

Jun 2022—

Sep 2022—

Dec 202218%

Mar 202317%

Jun 2023—

Sep 202316%

Dec 202317%

Mar 202417%

Jun 202419%

Sep 202416%

Dec 202419%

Mar 202517%

Jun 202519%

Sep 202514%

Dec 202514%

Mar 202612%

Jun 2026—

Anuh Pharma Ltd · ANUHPHR⚠ unverified

Sep 20218.9%

Dec 2021—

Mar 202217%

Jun 2022—

Sep 202218%

Dec 2022—

Mar 202318%

Jun 2023—

Sep 202320%

Dec 202329%

Mar 202423%

Jun 202428%

Sep 202421%

Dec 202422%

Mar 202517%

Jun 202519%

Sep 202515%

Dec 202518%

Mar 202613%

Jun 2026—

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 202110%

Dec 2021—

Mar 20227.2%

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023-2.3%

Jun 2023—

Sep 2023-4.0%

Dec 20231.8%

Mar 20240.8%

Jun 2024-0.6%

Sep 20247.1%

Dec 202418%

Mar 202523%

Jun 202534%

Sep 202530%

Dec 202529%

Mar 202618%

Jun 2026—

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 202154%

Dec 2021—

Mar 202254%

Jun 2022—

Sep 202251%

Dec 2022—

Mar 202348%

Jun 2023—

Sep 202336%

Dec 202347%

Mar 202437%

Jun 202442%

Sep 202430%

Dec 202434%

Mar 202523%

Jun 202524%

Sep 202519%

Dec 202523%

Mar 202615%

Jun 2026—

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 20219.0%

Dec 2021—

Mar 20226.3%

Jun 2022—

Sep 20225.4%

Dec 2022—

Mar 202313%

Jun 2023—

Sep 202314%

Dec 202313%

Mar 202422%

Jun 202451%

Sep 202410%

Dec 202443%

Mar 2025-3.6%

Jun 202519%

Sep 2025-2.3%

Dec 202521%

Mar 2026-0.1%

Jun 2026—

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 20226.1%

Jun 2022—

Sep 2022—

Dec 2022—

Mar 202326%

Jun 202317%

Sep 202316%

Dec 202326%

Mar 202414%

Jun 202419%

Sep 202414%

Dec 202418%

Mar 202513%

Jun 202516%

Sep 202513%

Dec 202516%

Mar 202614%

Jun 2026—

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 202124%

Dec 2021—

Mar 202218%

Jun 2022—

Sep 202217%

Dec 2022—

Mar 202320%

Jun 2023—

Sep 202317%

Dec 202320%

Mar 202411%

Jun 202415%

Sep 202414%

Dec 202434%

Mar 202517%

Jun 202534%

Sep 202517%

Dec 202523%

Mar 202617%

Jun 2026—

Kopran Ltd · KOPRAN⚠ unverified

Sep 202122%

Dec 2021—

Mar 202217%

Jun 2022—

Sep 202216%

Dec 2022—

Mar 20239.6%

Jun 2023—

Sep 20239.2%

Dec 202313%

Mar 202413%

Jun 202418%

Sep 202413%

Dec 202414%

Mar 202511%

Jun 202511%

Sep 20257.8%

Dec 20256.1%

Mar 202611%

Jun 2026—

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021-6.2%

Dec 2021—

Mar 2022-3.5%

Jun 2022—

Sep 2022-1.3%

Dec 2022—

Mar 2023—

Jun 2023—

Sep 20232.8%

Dec 202313%

Mar 20246.0%

Jun 202412%

Sep 20246.9%

Dec 20249.3%

Mar 20255.9%

Jun 20255.5%

Sep 20252.1%

Dec 20250.7%

Mar 20260.3%

Jun 2026—

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 202128%

Dec 2021—

Mar 202227%

Jun 2022—

Sep 202218%

Dec 2022—

Mar 202315%

Jun 2023—

Sep 202312%

Dec 202317%

Mar 20249.5%

Jun 202418%

Sep 202412%

Dec 202416%

Mar 20259.1%

Jun 20250.9%

Sep 2025-5.0%

Dec 2025-1.9%

Mar 2026-2.3%

Jun 2026—

Wanbury Ltd · WANBURY⚠ unverified

Sep 2021-92%

Dec 2021—

Mar 2022130%

Jun 2022—

Sep 2022-84%

Dec 2022—

Mar 2023146%

Jun 2023173%

Sep 202346%

Dec 202394%

Mar 202445%

Jun 202481%

Sep 202434%

Dec 202440%

Mar 202527%

Jun 202543%

Sep 202531%

Dec 202542%

Mar 202629%

Jun 2026—

ROCE change · reported quarter history

Aarti Drugs Ltd · AARTIDRUGS

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−4.9 pp

Dec 2022—

Mar 2023−5.4 pp

Jun 2023—

Sep 2023−2.5 pp

Dec 2023—

Mar 2024−1.1 pp

Jun 2024—

Sep 2024−3.8 pp

Dec 2024−4.4 pp

Mar 2025−2.9 pp

Jun 2025−1.0 pp

Sep 2025−0.5 pp

Dec 2025−1.1 pp

Mar 2026−0.4 pp

Jun 2026—

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022+12.8 pp

Mar 2023+5.7 pp

Jun 2023—

Sep 2023—

Dec 2023−1.7 pp

Mar 2024−0.4 pp

Jun 2024—

Sep 20240.0 pp

Dec 2024+2.5 pp

Mar 2025+0.2 pp

Jun 2025−0.1 pp

Sep 2025−1.2 pp

Dec 2025−5.1 pp

Mar 2026−5.1 pp

Jun 2026—

Anuh Pharma Ltd · ANUHPHR⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+9.5 pp

Dec 2022—

Mar 2023+1.0 pp

Jun 2023—

Sep 2023+1.6 pp

Dec 2023—

Mar 2024+4.9 pp

Jun 2024—

Sep 2024+0.6 pp

Dec 2024−7.0 pp

Mar 2025−6.1 pp

Jun 2025−8.9 pp

Sep 2025−6.0 pp

Dec 2025−4.6 pp

Mar 2026−3.3 pp

Jun 2026—

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023−9.5 pp

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024+3.1 pp

Jun 2024—

Sep 2024+11.1 pp

Dec 2024+16.6 pp

Mar 2025+21.7 pp

Jun 2025+34.3 pp

Sep 2025+22.6 pp

Dec 2025+10.6 pp

Mar 2026−4.7 pp

Jun 2026—

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−3.1 pp

Dec 2022—

Mar 2023−6.1 pp

Jun 2023—

Sep 2023−14.9 pp

Dec 2023—

Mar 2024−10.9 pp

Jun 2024—

Sep 2024−5.8 pp

Dec 2024−13.0 pp

Mar 2025−13.8 pp

Jun 2025−17.3 pp

Sep 2025−11.3 pp

Dec 2025−11.4 pp

Mar 2026−8.1 pp

Jun 2026—

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−3.6 pp

Dec 2022—

Mar 2023+6.2 pp

Jun 2023—

Sep 2023+8.2 pp

Dec 2023—

Mar 2024+9.5 pp

Jun 2024—

Sep 2024−3.3 pp

Dec 2024+29.6 pp

Mar 2025−25.6 pp

Jun 2025−31.9 pp

Sep 2025−12.6 pp

Dec 2025−22.2 pp

Mar 2026+3.5 pp

Jun 2026—

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023+19.5 pp

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024−12.1 pp

Jun 2024+1.6 pp

Sep 2024−1.9 pp

Dec 2024−7.8 pp

Mar 2025−0.3 pp

Jun 2025−2.7 pp

Sep 2025−1.5 pp

Dec 2025−2.3 pp

Mar 2026+0.4 pp

Jun 2026—

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−7.6 pp

Dec 2022—

Mar 2023+2.3 pp

Jun 2023—

Sep 2023+0.3 pp

Dec 2023—

Mar 2024−8.9 pp

Jun 2024—

Sep 2024−3.3 pp

Dec 2024+13.8 pp

Mar 2025+6.1 pp

Jun 2025+19.4 pp

Sep 2025+3.7 pp

Dec 2025−10.7 pp

Mar 2026−0.1 pp

Jun 2026—

Kopran Ltd · KOPRAN⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−5.4 pp

Dec 2022—

Mar 2023−7.1 pp

Jun 2023—

Sep 2023−7.0 pp

Dec 2023—

Mar 2024+3.4 pp

Jun 2024—

Sep 2024+4.0 pp

Dec 2024+1.2 pp

Mar 2025−2.4 pp

Jun 2025−7.1 pp

Sep 2025−5.4 pp

Dec 2025−8.3 pp

Mar 2026+0.1 pp

Jun 2026—

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.9 pp

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023+4.1 pp

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024+4.1 pp

Dec 2024−4.0 pp

Mar 2025−0.1 pp

Jun 2025−6.0 pp

Sep 2025−4.8 pp

Dec 2025−8.6 pp

Mar 2026−5.6 pp

Jun 2026—

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−9.8 pp

Dec 2022—

Mar 2023−11.9 pp

Jun 2023—

Sep 2023−6.3 pp

Dec 2023—

Mar 2024−5.7 pp

Jun 2024—

Sep 2024−0.2 pp

Dec 2024−1.0 pp

Mar 2025−0.4 pp

Jun 2025−17.1 pp

Sep 2025−16.9 pp

Dec 2025−18.3 pp

Mar 2026−11.4 pp

Jun 2026—

Wanbury Ltd · WANBURY⚠ unverified

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+7.4 pp

Dec 2022—

Mar 2023+16.1 pp

Jun 2023—

Sep 2023+129.8 pp

Dec 2023—

Mar 2024−101.3 pp

Jun 2024−91.9 pp

Sep 2024−12.1 pp

Dec 2024−53.9 pp

Mar 2025−18.0 pp

Jun 2025−38.3 pp

Sep 2025−3.1 pp

Dec 2025+2.0 pp

Mar 2026+2.4 pp

Jun 2026—

10 · compare level, then change

Valuation Against Growth & Quality

Orchid Pharma Ltd has the lowest PEG among the 14 Pharma - API companies compared here, at 1.77×. Aarti Drugs Ltd is next at 2.4×. Wanbury Ltd has the lowest P/E at 15.4×, so level and change sit with different companies. 5 of 14 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Orchid Pharma Ltd has the lowest comparable PEG at 1.77×, 26.2% below Aarti Drugs Ltd. Only 5 of 14 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderOrchid Pharma Ltd · 1.77×

Gap26.2% versus #2 · Aarti Drugs Ltd

Persistence0/8 recent comparable periods

Coverage5/14 companies · 34 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

PEGlowest PEG

1Orchid Pharma Ltd ORCHPHARMA1.8

2Aarti Drugs Ltd AARTIDRUGS2.4

3Gujarat Themis Biosyn Ltd GUJTHEM2.6

4Innova Captab Ltd INNOVACAP4.1

5Aarti Pharmalabs Ltd AARTIPHARM5.5

P/Elowest P/E

1Wanbury Ltd WANBURY⚠ unverified15.4

2Anuh Pharma Ltd ANUHPHR⚠ unverified17.3

3Aarti Drugs Ltd AARTIDRUGS19.7

4Fermenta Biotech Ltd FERMENTA⚠ unverified24.2

5Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified31.8

Valuation · company comparison

5/14 level · 14/14 change

All-company data · latest reported quarter

Company	PEG	P/E	Reported
Aarti Pharmalabs Ltd AARTIPHARM	5.5	35.4	Jun 2026
Innova Captab Ltd INNOVACAP	4.1	38.4	Jun 2026
Gujarat Themis Biosyn Ltd GUJTHEM	2.6	91.7	Jun 2026
Aarti Drugs Ltd AARTIDRUGS	2.4	17.4	Jun 2026
Orchid Pharma Ltd ORCHPHARMA	1.8	282.5	Jun 2026
Senores Pharmaceuticals Ltd SENORES	—	50.7	Jun 2026
Beta Drugs Ltd BETA	—	51.2	Jun 2026
Ind-Swift Laboratories Ltd INDSWFTLAB⚠ unverified	—	35.2	Jun 2026
Jagsonpal Pharmaceuticals Ltd JAGSNPHARM⚠ unverified	—	33.5	Jun 2026
Fermenta Biotech Ltd FERMENTA⚠ unverified	—	16.1	Jun 2026
Themis Medicare Ltd THEMISMED⚠ unverified	—	530.4	Jun 2026
Kopran Ltd KOPRAN⚠ unverified	—	35.6	Jun 2026
Wanbury Ltd WANBURY⚠ unverified	—	13.7	Jun 2026
Anuh Pharma Ltd ANUHPHR⚠ unverified	—	19.1	Jun 2026

Full 20-quarter history · every available company

PEG · reported quarter history

Aarti Drugs Ltd · AARTIDRUGS

Sep 20211.1

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20250.6

Jun 2025—

Sep 20253.2

Dec 20252.4

Mar 2026—

Jun 2026—

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 20230.3

Jun 2023—

Sep 2023—

Dec 20232.3

Mar 20240.4

Jun 20241.4

Sep 20241.5

Dec 20241.3

Mar 20251.0

Jun 20251.1

Sep 20251.5

Dec 20255.5

Mar 2026—

Jun 2026—

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 20210.6

Dec 20212.7

Mar 2022—

Jun 20220.3

Sep 20220.6

Dec 20220.6

Mar 20230.9

Jun 2023—

Sep 20231.5

Dec 2023—

Mar 20241.4

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 20252.6

Dec 2025—

Mar 2026—

Jun 2026—

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 20235.2

Mar 20240.8

Jun 20240.7

Sep 20241.4

Dec 20241.5

Mar 2025—

Jun 20251.5

Sep 20252.2

Dec 20251.3

Mar 20261.0

Jun 20264.1

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20251.8

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Jun 2026—

P/E · reported quarter history

Showing the 12 largest of 14 companies with a series here. The remaining 2 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

Aarti Drugs Ltd · AARTIDRUGS

Sep 202123.4

Dec 202124.0

Mar 202220.2

Jun 202217.7

Sep 202222.7

Dec 202222.8

Mar 202318.9

Jun 202325.9

Sep 202328.0

Dec 202325.1

Mar 202422.2

Jun 202427.1

Sep 202430.1

Dec 202427.1

Mar 202520.5

Jun 202524.3

Sep 202525.5

Dec 202522.6

Mar 202614.9

Jun 202617.4

Aarti Pharmalabs Ltd · AARTIPHARM

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 202312.9

Jun 202317.4

Sep 202321.6

Dec 202324.1

Mar 202420.3

Jun 202425.5

Sep 202424.8

Dec 202426.9

Mar 202527.2

Jun 202528.6

Sep 202528.0

Dec 202528.1

Mar 202625.6

Jun 202635.4

Beta Drugs Ltd · BETA

Sep 202136.1

Dec 2021—

Mar 202228.5

Jun 2022—

Sep 202229.8

Dec 2022—

Mar 202320.9

Jun 2023—

Sep 202331.8

Dec 2023—

Mar 202438.6

Jun 2024—

Sep 202444.2

Dec 202454.7

Mar 202552.8

Jun 202539.2

Sep 202540.0

Dec 202534.7

Mar 202627.3

Jun 202651.2

Fermenta Biotech Ltd · FERMENTA⚠ unverified

Sep 202118.7

Dec 202125.9

Mar 202242.5

Jun 202237.2

Sep 202236.9

Dec 2022—

Mar 2023—

Jun 2023-8.4

Sep 2023—

Dec 2023-24.0

Mar 2024—

Jun 2024—

Sep 2024105.3

Dec 2024128.9

Mar 202522.7

Jun 202512.4

Sep 20258.9

Dec 20259.4

Mar 202611.4

Jun 202616.1

Gujarat Themis Biosyn Ltd · GUJTHEM

Sep 202122.3

Dec 202117.5

Mar 202213.6

Jun 202212.9

Sep 202217.3

Dec 202220.1

Mar 202317.2

Jun 202319.9

Sep 202328.7

Dec 202333.9

Mar 202448.6

Jun 202462.3

Sep 202476.2

Dec 202463.2

Mar 202562.9

Jun 202584.9

Sep 202589.6

Dec 2025100.9

Mar 202653.1

Jun 202691.7

Ind-Swift Laboratories Ltd · INDSWFTLAB⚠ unverified

Sep 202134.0

Dec 202115.7

Mar 202212.9

Jun 202211.4

Sep 2022-1,632.7

Dec 202236.4

Mar 202328.9

Jun 202315.4

Sep 202317.5

Dec 202316.6

Mar 202420.6

Jun 20243.7

Sep 20244.1

Dec 20243.9

Mar 20253.7

Jun 20254.8

Sep 202527.6

Dec 202520.2

Mar 202620.0

Jun 202635.2

Innova Captab Ltd · INNOVACAP

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 202339.2

Mar 202432.5

Jun 202428.5

Sep 202440.0

Dec 202452.3

Mar 202539.5

Jun 202538.4

Sep 202537.7

Dec 202531.6

Mar 202629.9

Jun 202638.4

Jagsonpal Pharmaceuticals Ltd · JAGSNPHARM⚠ unverified

Sep 202118.5

Dec 202119.6

Mar 202231.6

Jun 202240.2

Sep 202255.2

Dec 202246.7

Mar 202332.6

Jun 202334.7

Sep 202335.1

Dec 202335.9

Mar 202429.6

Jun 202439.5

Sep 202447.9

Dec 202463.2

Mar 202539.5

Jun 202536.8

Sep 202533.5

Dec 202529.9

Mar 202628.9

Jun 202633.5

Kopran Ltd · KOPRAN⚠ unverified

Sep 202116.6

Dec 202125.8

Mar 202222.1

Jun 202214.1

Sep 202211.5

Dec 202213.9

Mar 202314.5

Jun 202333.0

Sep 202348.8

Dec 202336.9

Mar 202430.9

Jun 202424.0

Sep 202427.1

Dec 202419.7

Mar 202517.8

Jun 202518.8

Sep 202521.7

Dec 202518.6

Mar 202614.2

Jun 202635.6

Orchid Pharma Ltd · ORCHPHARMA

Sep 2021-66.1

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022-76.6

Mar 2023—

Jun 2023147.0

Sep 202359.5

Dec 202350.3

Mar 202457.7

Jun 202463.1

Sep 202464.8

Dec 202477.2

Mar 202535.7

Jun 202536.0

Sep 202556.6

Dec 2025122.2

Mar 2026473.9

Jun 2026282.5

Senores Pharmaceuticals Ltd · SENORES

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 202455.1

Mar 202555.3

Jun 202539.7

Sep 202544.0

Dec 202543.5

Mar 202635.7

Jun 202650.7

Themis Medicare Ltd · THEMISMED⚠ unverified

Sep 202115.8

Dec 202112.3

Mar 202212.1

Jun 20229.2

Sep 202215.9

Dec 202221.6

Mar 202318.6

Jun 202322.0

Sep 202328.8

Dec 202338.4

Mar 202444.4

Jun 202444.3

Sep 202451.9

Dec 202445.9

Mar 202529.3

Jun 202540.0

Sep 202536.1

Dec 2025-53.3

Mar 2026530.4

Jun 2026—

11 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Pharma - API comparison names 6 specific ways its own evidence can mislead, all listed below. All 14 companies here report on comparable dates, so no rank carries a stale marker. 7 draw at least one figure from a second feed with too little overlap to cross-check. 2 have second-feed figures withheld because the two sources disagree.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
7 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.

12 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 14 Pharma - API companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company

Market dataThrough 2026-08-14 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

Source standing5 cross-checked · 7 unverified · 2 withheld, of 14 graded companies.

How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

13 · questions investors ask, short speakable answers

Pharma - API company comparison FAQs

These 24 answers restate the Pharma - API comparison above in question form. Every one is computed from the same 14 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.

Is the Pharma - API sector outperforming NIFTY 500?

Pharma - API has outperformed NIFTY 500 by 27.3% over 52 weeks and 26% over 13 weeks. 11 of 14 covered companies beat NIFTY on Mansfield relative strength, while 5 of 14 beat the sector itself.

Which Pharma - API company is largest by revenue?

Aarti Drugs Ltd leads with revenue of ₹2,678 crore, based on 14 of 14 comparable companies through Jun 2026.

Which Pharma - API company is growing fastest?

Ind-Swift Laboratories Ltd has the fastest current revenue growth at 53.9%, across 14 of 14 comparable companies.

Which Pharma - API company has the strongest 4-Factor Sector Score?

Senores Pharmaceuticals Ltd ranks first at 73.2/100 with 75.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Pharma - API company has the lowest comparable PEG?

Orchid Pharma Ltd has the lowest comparable PEG at 1.77, among 5 of 14 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Pharma - API comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Is there a Nifty Pharma - API index?

NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharma - API, this page builds its own equal-weight basket of 14 listed Pharma - API companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.

Which are the best Pharma - API stocks in India?

Ranked by this page's four-factor score, Senores Pharmaceuticals Ltd places first among 14 listed Pharma - API companies, followed by Wanbury Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Pharma - API stocks are listed in India?

This comparison covers 14 listed Pharma - API companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Pharma - API company is the biggest?

Aarti Drugs Ltd is the largest, with trailing-twelve-month revenue of ₹2,678 crore, ahead of Aarti Pharmalabs Ltd at ₹1,969 crore. That covers 14 of 14 companies with comparable reporting through Jun 2026.

Which Pharma - API company has the best profit margins?

Gujarat Themis Biosyn Ltd has the highest operating margin at 48%, from 14 of 14 comparable companies. Ind-Swift Laboratories Ltd shows the biggest recent improvement, at +14.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Pharma - API company makes the most profit?

Aarti Pharmalabs Ltd earns the most, at ₹213 crore of trailing-twelve-month net profit, from 14 of 14 comparable companies. Senores Pharmaceuticals Ltd has the fastest profit growth at 92.7%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Pharma - API company earns the highest return on capital?

Wanbury Ltd leads on return on capital employed at 30.8%, across 14 of 14 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Pharma - API stock is the cheapest?

On PEG — where a LOWER number is cheaper — Orchid Pharma Ltd screens cheapest at 1.77×. Only 5 of 14 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Pharma - API sector beating the market?

Pharma - API has outperformed NIFTY 500 by 27.3% over the last 52 weeks and 26% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 11 of 14 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Pharma - API stock has the strongest price momentum?

Ind-Swift Laboratories Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Pharma - API company scores highest for research priority?

Senores Pharmaceuticals Ltd scores 73.2 out of 100 with 75.3% evidence confidence, from 32.4 points on growth and earnings, 17 on capital efficiency, 9.4 on valuation and 14.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Pharma - API companies does this comparison cover, and over what period?

It compares 14 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Pharma - API sector?

The 14 Pharma - API companies on this page carry ₹49,872 crore of combined market value. Orchid Pharma Ltd is the largest at ₹9,966 crore, about 20% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-18.

What is the Pharma - API sector's P/E ratio?

The median price-to-earnings ratio across the 14 Pharma - API companies on this page is 38.5×, measured on the 14 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-18.

How is the Pharma - API sector performing?

11 of the 14 covered Pharma - API companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 27.3% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-18.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.